GREENFIELD, Ind. , Dec. 19, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 43 rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 . Jeff Simmons , president and CEO, will represent the company and respond to questions from analysts at 3:00 p.m. PST ( 6:00 PM EST ). A live audio webcast will be available in the "Events and Presentations" section of Elanco's... Read More

GREENFIELD, Ind , Nov. 25, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that management will participate in upcoming investor conferences. On Tuesday, December 3 , Todd Young , executive vice president and CFO, will participate in a fireside chat at the Evercore ISI 7th Annual HealthCONx at 11:15 a.m. ET . On Thursday, December 5 , Todd Young will participate in the Piper Sandler 36 th... Read More

GREENFIELD, Ind. , Nov. 15, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today acquired a contract manufacturing facility and related assets in Speke, UK. The facility, previously owned by TriRx Speke Ltd., was under trading administration, a formal insolvency process in the United Kingdom . As previously shared on the Company's third quarter 2024 earnings call, the Speke facility plays a vital role... Read More

Ma brings deep manufacturing and innovation expertise GREENFIELD, Ind. , Nov. 12, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the appointment of Dr. Stacey Ma to its Board of Directors, effective immediately. Dr. Ma brings extensive global leadership experience in biopharmaceutical... Read More

Third Quarter 2024 Financial Results Revenue of $1,030 million , organic constant currency growth of 1% Reported Net Income of $364 million , Adjusted Net Income of $66 million Adjusted EBITDA of $163 million , or 15.8% of Revenue Reported EPS of $0.73 , Adjusted EPS of $0.13 Net leverage ratio of 4.3x Adjusted EBITDA Pre-tax gain of $640 million from July 2024 divestiture of the aqua business Tightening full year 2024... Read More

GREENFIELD, Ind. , Oct. 10, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its third quarter 2024 financial results on Thursday, November 7, 2024 . Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time . Investors, media, and the general public can... Read More

Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) is the first and only canine oral parasiticide to protect against six parasites, including fleas, ticks, heartworms, roundworms, hookworms ii and three different species of tapeworm that other brands skip creating a gap in coverage iii... Read More

U.S. Food and Drug Administration approves Zenrelia, a once-daily oral JAK inhibitor for dogs with allergic and atopic dermatitis Elanco enters the estimated $1.7 billion global canine dermatology market, highly accretive to existing portfolio In a head-to-head study, Zenrelia was shown to be at least as effective as the... Read More

GREENFIELD, Ind. , Sept. 13, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today provided an update on its relationship with contract manufacturing supplier, TriRx Speke Ltd (TriRx). TriRx today entered into trading administration, a formal insolvency process in the United Kingdom designed to help companies facing severe financial challenges regain stability. Administrators from FTI Consulting LLP have... Read More

GREENFIELD, Ind. , Aug. 28, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Morgan Stanley 22 nd Annual Global Healthcare Conference, September 4-5, 2024 . Jeff Simmons , President and CEO, and Todd Young , executive vice president and CFO, will participate in a fireside chat on Thursday, September 5 at 3:20 p.m. ET . A live audio webcast will be available in the "Events and Presentations"... Read More

Company's broad spectrum parasiticide on-track for October U.S. approval and first quarter 2025 launch GREENFIELD, Ind. , Aug. 20, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S. Food and Drug Administration (FDA) has completed its review of all major and minor technical sections for Credelio Quattro, and the final 60-day administrative review is underway. "This is an exciting... Read More

Study finds that the aggressive lone star tick is no match for Credelio GREENFIELD, Ind. , Aug. 15, 2024 /PRNewswire/ -- Parasites & Vectors , a leading peer-reviewed journal focused on parasites and vector-borne pathogens published the results of a head-to-head study demonstrating that Credelio, a prescription flea and tick... Read More

Raises Full Year Revenue and Maintains Adjusted EBITDA Guidance Excluding Aqua Divestiture Second Quarter 2024 Financial Results Revenue of $1,184 million Reported Net Loss of $50 million , Adjusted Net Income of $147 million Adjusted EBITDA of $275 million , or 23.2% of Revenue Reported EPS of $(0.10) , Adjusted EPS of $0.30 Net leverage ratio of 5.6x Adjusted EBITDA Year over year growth rates are meaningfully impacted by... Read More

GREENFIELD, Ind. , July 30, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today released its 2023 Environmental, Social and Governance (ESG) Report , showcasing its dedication to advancing its four intertwined Healthy Purpose™ Pillars: Healthier Animals, Healthier People, Healthier Planet and Healthier... Read More

GREENFIELD, Ind. , July 18, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its second quarter 2024 financial results on Thursday, August 8, 2024 . Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time . Investors, media, and the general public can... Read More

Transaction concentrates Elanco's focus on significant value creation opportunities and accelerates deleveraging progress GREENFIELD, Ind. , July 9, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) announced today it has completed the divestiture of its aqua business to Merck Animal Health (NYSE: MRK) for approximately $1.3 billion in cash, with approximately $1.05 - $1.1 billion in net proceeds available... Read More

Major technical sections complete for Zenrelia, with FDA final approval on track for late in third quarter of 2024; updates on differentiation and safety Final FDA approval for Credelio Quattro now expected in the fourth quarter of 2024 First Zenrelia approval received in Brazil 2024 Innovation sales guidance increased GREENFIELD, Ind. , June 27, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today... Read More

GREENFIELD, Ind. , June 6, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Goldman Sachs 45th Annual Global Healthcare Conference, June 11-12, 2024 . Jeff Simmons , President and CEO, will participate in a fireside chat on Tuesday, June 11 at 2:40 p.m. ET . A live audio webcast will be available in the "Events and Presentations" section of Elanco's investor website . A replay will be... Read More

Food and Drug Administration confirms Bovaer meets safety and efficacy requirements Elanco expects product launch and added carbon credit value to producers beginning in the third quarter Elanco announces agreement with dsm-firmenich to expand distribution of Bovaer across North America , adding both the Canada and Mexico... Read More

GREENFIELD, Ind. , May 21, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Stifel 2024 Jaws and Paws Conference on Wednesday, May 29, 2024 . Todd Young , executive vice president and CFO, will participate in a fireside chat at 8:00 a.m. ET . A live audio webcast will be available in the "Events and Presentations" section of Elanco's investor website . A replay will be available for... Read More

First Quarter 2024 Financial Results Revenue of $1,205 million Reported Net income of $32 million , Adjusted Net income of $167 million Adjusted EBITDA of $294 million , or 24.4% of Revenue Reported EPS of $0.06 , Adjusted EPS of $0.34 Net leverage ratio of 6.1x Adjusted EBITDA Year over year growth rates are meaningfully impacted by a shift in customer purchasing related to the ERP Blackout in 2023, with an estimated $90 to... Read More

Launches first-ever tracking site for often-fatal parvovirus outbreaks to Save 1 Million Puppies by 2030 GREENFIELD, Ind. , April 23, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today unleashed a multi-faceted educational campaign – declaring today as the first-ever National Parvo Awareness Day, aimed... Read More

GREENFIELD, Ind. , April 17, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024 . Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time . Investors, media, and the general public can... Read More

New Directors Join the Board's Renamed Finance, Strategy and Oversight Committee Reaches Cooperation Agreement with Ancora GREENFIELD, Ind. , April 1, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that it has appointed two new independent directors, Kathy Turner and Craig Wallace , to its Board of Directors (the "Board"), effective immediately, expanding the Board to 14 members. Ms.... Read More

GREENFIELD, Ind. , March 4, 2024 /PRNewswire/ -- Elanco Animal Health (NYSE: ELAN) announced today the appointment of Shiv O'Neill as the company's Executive Vice President, General Counsel and Corporate Secretary. O'Neill will be responsible for the global strategy and operations of the Company's legal team, ethics & compliance organization and ESG efforts. "Shiv's ability to deliver strategic value to Elanco in the short... Read More

Ancora Nominates Director Candidates Despite Elanco's Meaningful Operational Progress and Good Faith Engagement with the Investor GREENFIELD, Ind. , Feb. 29, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today issued the following statement in response to the submission of four nominees to the Company's Board of Directors by Ancora Holdings Group, LLC ("Ancora"): The execution of Elanco's Innovation,... Read More

Fourth Quarter 2023 Financial Results: Revenue of $1,035 million Reported Net Loss of $141 million , Adjusted Net Income of $39 million Adjusted EBITDA of $165 million or 15.9% of Revenue Reported EPS of $(0.29) , Adjusted EPS of $0 .08 Net leverage ratio of 5.6x Adjusted EBITDA Full Year 2023 Financial Results: Revenue of $4,417 million Reported Net Loss of $1,231 million , Adjusted Net Income of $439 million Adjusted... Read More

GREENFIELD, Ind. , Feb. 22, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that the Company will participate in the following investor conferences. On Thursday, February 29 , Todd Young , executive vice president and CFO, will participate in a fireside chat at the Bank of America 2024 Animal Health Summit at 2:10 p.m. ET . On Monday, March 4 , Jeff Simmons , president and CEO, will... Read More

SARATOGA, Calif. , Feb. 8, 2024 /PRNewswire/ -- Cattler ( www.cattler.farm ) announces the launch of its interface with Elanco Animal Health Incorporated (NYSE: ELAN), as part of the agreement reached September 2023 , to provide data collaboration for customers participating in Elanco Knowledge Solutions (EKS) services that include (but are not limited to) Benchmark TM and Experior TM Data Services. This interface provides... Read More

GREENFIELD, Ind. , Feb. 8, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its fourth quarter and full year 2023 financial results on Monday, February 26, 2024 . Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time . Investors, media, and the general... Read More

Transaction reinforces Elanco's commitment to most significant value creation opportunities in pet health and livestock sustainability Enables company to accelerate debt paydown by $1.05B to $1.1B GREENFIELD, Ind. , Feb. 5, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has entered into an agreement to sell its aqua business to Merck Animal Health (NYSE: MRK) for approximately $1.3... Read More

Calling all Veterinarians and Pet Lovers - Take the "Defend Puppies. Defeat Parvo." Pledge Today to Save Puppies from Deadly Canine Parvovirus GREENFIELD, Ind. , Jan. 17, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today launched the first-of-its-kind, multi-year campaign to save 1 million puppies from... Read More

Lawrence Kurzius to become next Chairman of the Board GREENFIELD, Ind. , Jan. 2, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) announced today that the Board of Directors has named Lawrence E. Kurzius as its next Chairman of the Board, effective at the conclusion of the Company's 2024 Annual Meeting of Shareholders. Mr. Kurzius, a member of the Elanco Board since 2018, will succeed current Chairman, R.... Read More

GREENFIELD, Ind. / Dec 19, 2023 / Business Wire / Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 42 nd Annual J.P. Morgan Healthcare Conference on January 8-10, 2024. Jeff Simmons, president and CEO, will represent the company and respond to questions from analysts on Tuesday, January 9, 2024 at 3:00 p.m. PST (6:00 PM EST). A live audio webcast will be available in the “Events and Presentations”... Read More

GREENFIELD, Ind. / Nov 27, 2023 / Business Wire / Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Evercore ISI 6th Annual HealthCONx Conference, November 28-29, 2023. Todd Young, Executive Vice President and CFO, will participate in a fireside chat on Wednesday, November 29 at 8:20 a.m. ET. A live audio webcast will be available in the “Events and Presentations” section of Elanco’s investor website . A replay... Read More

Third Quarter 2023 Financial Results Revenue of $1,068 million, representing 4% reported growth or 5% excluding the impact of foreign exchange rates Reported Net Loss of $1,096 million, inclusive of a non-cash goodwill impairment charge of $1,042 million primarily related to increased long-term treasury rates Adjusted EBITDA of $214 million, or 20.0% of Revenue Reported EPS of $(2.22) inclusive of a $(2.10) per share impact... Read More

LOS ANGELES, Nov. 02, 2023 (GLOBE NEWSWIRE) -- The Pet Innovation Awards, an independent recognition platform highlighting the most innovative companies, services, and products in the highly competitive Pet Care industry, today announced it has awarded “Overall Cat Health Product of the Year” to Bexacat™, the first and only oral prescription tablet to improve glycemic control in cats with diabetes mellitus (DM) not... Read More

GREENFIELD, Ind. / Oct 17, 2023 / Business Wire / Elanco Animal Health Incorporated (NYSE: ELAN) will announce its third quarter 2023 financial results on Tuesday, November 7, 2023. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company’s performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can... Read More

GREENFIELD, Ind. / Oct 04, 2023 / Business Wire / Elanco Animal Health Incorporated (NYSE: ELAN) announced today that the Board of Directors has commenced a process to amend the Company’s corporate governing documents as part of a comprehensive governance review following the Company’s 2023 Annual Meeting of Shareholders. The Board expects to seek shareholder approval at the 2024 Annual Meeting of Shareholders for amendments... Read More

GREENFIELD, Ind. / Sep 07, 2023 / Business Wire / Today, Elanco Animal Health Incorporated (NYSE: ELAN) announced that the first shipments of Varenzin™-CA1 (molidustat oral suspension), conditionally approved by U.S. Food and Drug Administration (FDA) as the first and only treatment to control non-regenerative anemia in cats with chronic kidney disease (CKD), are shipping to veterinary clinics around the country. Anemia from... Read More

GREENFIELD, Ind. / Sep 05, 2023 / Business Wire / Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, September 11, 2023 and Tuesday, September 12, 2023. Jeff Simmons, president and CEO, will participate in a fireside chat on Monday at 4:15 p.m. ET. A live audio webcast will be available in the “Events and Presentations” section of Elanco’s... Read More

Second Quarter 2023 Financial Results Revenue of $1,057 million, impacted by an estimated $90-$110 million of revenue related to customer purchasing shifted from the second quarter into the first as a result of ERP system commercial ordering blackout period for legacy Bayer Animal Health products in April Reported Net Loss of $(97) million, Adjusted Net Income of $90 million Adjusted EBITDA of $222 million or 21.0% of... Read More

GREENFIELD, Ind. / Jul 20, 2023 / Business Wire / Elanco Animal Health Incorporated (NYSE:ELAN) today released its 2022 Environmental, Social and Governance (ESG) Report highlighting enhanced governance, transparency and progress measurements. Elanco’s commitment to important ESG-related topics is demonstrated across its four interconnected Healthy Purpose™ Pillars: Healthier Animals, Healthier People, Healthier Planet and... Read More

GREENFIELD, Ind. / Jul 18, 2023 / Business Wire / Elanco Animal Health Incorporated (NYSE: ELAN) will announce its second quarter 2023 financial results on Monday, August 7, 2023. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company’s performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can... Read More

Comprehensive, multi-year review by the EPA, with support from the Food and Drug Administration, confirms Seresto continues to meet EPA standards for product registration Data affirms the safety profile of the product Expert toxicologists and veterinarians voice their support of Seresto’s safety profile Elanco and EPA forge... Read More

GREENFIELD, Ind. / Jun 05, 2023 / Business Wire / Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Goldman Sachs 44th Annual Global Healthcare Conference, June 12-13, 2023. Jeff Simmons, President and CEO, will participate in a fireside chat on Monday, June 12 at 5:40 p.m. ET (2:40 p.m. PT). A live audio webcast will be available in the “Events and Presentations” section of Elanco’s investor website . A replay... Read More

GREENFIELD, Ind. / May 25, 2023 / Business Wire / Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Stifel 2023 Jaws and Paws Conference on Thursday, June 1, 2023. Todd Young, executive vice president and CFO, will participate in a fireside chat at 1:50 p.m. ET. A live audio webcast will be available in the “Events and Presentations” section of Elanco’s investor website . A replay will be available for... Read More

First Quarter 2023 Financial Results Revenue of $1,257 million, including an estimated $90-$110 million benefit from customer purchasing shifted from the second quarter into the first as a result of ERP system commercial ordering blackout period for legacy Bayer Animal Health products in April Reported Net Income of $103 million, Adjusted Net Income of $220 million Adjusted EBITDA of $379 million or 30.2% of Revenue Reported... Read More

Targeted single-dose monoclonal antibody is the first and only treatment for devastating dog disease GREENFIELD, Ind. / May 02, 2023 / Business Wire / Elanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S. Department of Agriculture (USDA) has provided a conditional license for the first Canine Parvovirus... Read More

Athian's livestock carbon credit marketplace completes latest round of funding thanks to the investment by California Dairies, Inc. and DSM Venturing INDIANAPOLIS , May 1, 2023 /PRNewswire/ -- Athian ( athian.ai ) announces the completion of their seed funding round with investments from two strategic partners: DSM Venturing, the corporate venture arm of Royal DSM, a global, purpose-led company in Health, Nutrition &... Read More

GREENFIELD, Ind. / Apr 18, 2023 / Business Wire / Elanco Animal Health Incorporated (NYSE: ELAN) will announce its first quarter 2023 financial results on Tuesday, May 9, 2023. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company’s performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a... Read More

Will help fund ground-breaking solution to reward livestock producers for certified greenhouse gas reductions INDIANAPOLIS , March 14, 2023 /PRNewswire/ -- Athian (athian.ai), the world's first cloud-based carbon marketplace for the livestock industry, announces a seed investment from Tyson Ventures, the venture capital arm of Tyson Foods, Inc., one of the world's largest food companies and a recognized leader in protein.... Read More

GREENFIELD, Ind. / Mar 09, 2023 / Business Wire / Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Barclays Global Healthcare Conference on March 14-15, 2023. Todd Young, executive vice president and CFO, will participate in a fireside chat on Tuesday, March 14 at 8:30 a.m. ET. A live audio webcast will be available in the “Events and Presentations” section of Elanco’s investor website . A replay will be... Read More

GREENFIELD, Ind. / Feb 23, 2023 / Business Wire / Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Bank of America 2023 Animal Health Summit on Thursday, March 2, 2023. Jeff Simmons, president and CEO, and Todd Young, executive vice president and CFO, will represent the company and respond to questions from analysts at 4:40 p.m. ET. A live audio webcast will be available in the “Events and... Read More

GREENFIELD, Ind. / Feb 21, 2023 / Business Wire / Elanco Animal Health Incorporated (NYSE: ELAN) today reported its financial results for the fourth quarter and full year 2022, and provided initial guidance both for the first half and full year 2023. “Elanco’s 2022 results demonstrate our ongoing dedication to our Innovation, Portfolio, and Productivity (IPP) strategy, with significant advancement in our innovation pipeline... Read More

GREENFIELD, Ind. / Feb 20, 2023 / Business Wire / Elanco Animal Health (NYSE: ELAN) announced today the appointment of Tim Bettington as the company’s executive vice president Corporate Strategy and Market Development. He will join Elanco’s executive committee on March 20. As Elanco shifts from the separation and stand up of the independent company and the integration of the Bayer Animal Health acquisition to an increasing... Read More

GREENFIELD, Ind. / Feb 03, 2023 / Business Wire / Elanco Animal Health Incorporated (NYSE: ELAN) will announce its fourth quarter and full year 2022 financial results on Tuesday, February 21, 2023. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company’s performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the... Read More

Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 41 st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023. Jeff Simmons, president and CEO, will represent the company and respond to questions from analysts at 12:45 p.m. ET. A live audio webcast will be available in the “Events and Presentations” section of Elanco’s investor website . A replay will be available for approximately 30... Read More

GREENFIELD, Ind.--( BUSINESS WIRE )--Today Elanco Animal Health (NYSE:ELAN) announced the U.S. Food and Drug Administration (FDA) approved Bexacat™ (bexagliflozin tablets), the first orally administered prescription medication to improve glycemic control in cats with diabetes mellitus, expanding Elanco’s innovative feline portfolio while addressing an unmet need for this chronic condition in adult cats. An estimated 600,000... Read More